Loading…
Grand Pharmaceutical Group (远大医药) has entered a strategic partnership with CoRISMA MCS Systems, investing $12 million for a 22.2% stake and exclusive rights to develop and commercialize CoRISMA's heart failure treatment systems in Greater China and several Southeast Asian countries.
“该集团将以1200万美元为代价取得CoRISMA约22.2%的股权,后续会进一步投入以获得治疗心力衰竭的创新医疗器械CoRISMA系列产品在大中华区的独家开发、生产及商业化权益。”beta.zhitongcaijing.com
Summarized from public sources; check the original articles before acting on it.